Manzke, Jana, Stauf, Raphael, Neumann, Bernd ORCID: 0000-0002-3580-2105, Molitor, Ernst, Hischebeth, Gunnar, Simon, Michaela, Jantsch, Jonathan, Roedel, Juergen, Becker, Soeren L., Halfmann, Alexander, Wichelhaus, Thomas A., Hogardt, Michael, Serr, Annerose, Hess, Christina, Wendel, Andreas F., Siegel, Ekkehard, Rohde, Holger, Zimmermann, Stefan and Steinmann, Joerg (2022). German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay. Antibiotics-Basel, 11 (5). BASEL: MDPI. ISSN 2079-6382

Full text not available from this repository.

Abstract

Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftazidime-avibactam. Meropenem-resistant isolates of P. aeruginosa from various clinical materials were collected at 11 tertiary care hospitals in Germany from 2017-2019. Minimum inhibitory concentrations (MICs) were determined via microdilution plates (MICRONAUT-S) of ceftazidime-avibactam and meropenem at each center. Detection of the presence of carbapenemases was performed by PCR or immunochromatography. For meropenem-resistant isolates (n = 448), the MIC range of ceftazidime-avibactam was 0.25-128 mg/L, MIC90 was 128 mg/L and MIC50 was 16 mg/L. According to EUCAST clinical breakpoints, 213 of all meropenem-resistant P. aeruginosa isolates were categorized as susceptible (47.5%) to ceftazidime-avibactam. Metallo-beta-lactamases (MBL) could be detected in 122 isolates (27.3%). The MIC range of ceftazidime-avibactam in MBL-positive isolates was 4-128 mg/L, MIC90 was >128 mg/L and MIC50 was 32 mg/L. There was strong variation in the prevalence of MBL-positive isolates among centers. Our in vitro results support ceftazidime-avibactam as a treatment option against infections caused by meropenem-resistant, MBL-negative P. aeruginosa.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Manzke, JanaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stauf, RaphaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neumann, BerndUNSPECIFIEDorcid.org/0000-0002-3580-2105UNSPECIFIED
Molitor, ErnstUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hischebeth, GunnarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Simon, MichaelaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jantsch, JonathanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roedel, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Becker, Soeren L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Halfmann, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wichelhaus, Thomas A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hogardt, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Serr, AnneroseUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hess, ChristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wendel, Andreas F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siegel, EkkehardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rohde, HolgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zimmermann, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steinmann, JoergUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-694004
DOI: 10.3390/antibiotics11050545
Journal or Publication Title: Antibiotics-Basel
Volume: 11
Number: 5
Date: 2022
Publisher: MDPI
Place of Publication: BASEL
ISSN: 2079-6382
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
Infectious Diseases; Pharmacology & PharmacyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69400

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item